var data={"title":"Cefoxitin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefoxitin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5842?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">see &quot;Cefoxitin: Drug information&quot;</a> and <a href=\"topic.htm?path=cefoxitin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefoxitin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10327785\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mefoxin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965749\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cefoxitin For Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046026\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442225\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>General dosing; susceptible infection:</b> Limited data available: IV: 90 to 100 mg/kg/day divided every 8 hours (Regazzi 1983; Roos 1980)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046019\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">see &quot;Cefoxitin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Limited data available for infants &lt;3 months:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2012]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: 80 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: 160 mg/kg/day divided every 6 hours; maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;3 months, Children, and Adolescents: 80 to 160 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections, complicated:</b> Infants, Children, and Adolescents: IV: 160 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 8 <b>g/day</b> (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis, prophylaxis for patients receiving peritoneal dialysis undergoing gastrointestinal or genitourinary procedures:</b> Infants, Children, and Adolescents: IV: 30 to 40 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;3 months, Children, and Adolescents: 30 to 40 mg/kg 30 to 60 minutes prior to initial incision, followed by 30 to 40 mg/kg every 6 hours for up to 24 hours; maximum single dose: 2,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (ASHP guidelines, endorsed by IDSA): Children and Adolescents: 40 mg/kg within 60 minutes prior to surgery; may repeat in 2 hours if procedure is lengthy or if there is excessive blood loss; maximum single dose: 2,000 mg (Bratzler 2013; <i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IV: 1,000 to 2,000 mg every 6 to 8 hours; maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated infections: 1,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderately severe to severe infections: 1,000 mg every 4 hours <b>or</b> 2,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection needing higher dosages (eg, gas gangrene): 2,000 mg every 4 hours or 3,000 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease</b> (Workowski 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inpatients: IV: 2,000 mg every 6 hours <b>plus</b> doxycycline 100 mg orally every 12 hours until improved, followed by doxycycline to complete 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Outpatients: IM: 2,000 mg <b>plus</b> probenecid as a single dose, followed by doxycycline for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> IV: 2,000 mg 30 to 60 minutes prior to surgery; may repeat in 2 hours intraoperatively (Bratzler 2013), followed by 2,000 mg every 6 hours for no more than 24 hours after surgery depending on the procedure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cesarean section: 2,000 mg as a single dose administered as soon as the umbilical cord is clamped; may give an additional two doses at 4 and 8 hours after the initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The manufacturer's labeling suggests dosing modification consistent with the adult recommendations. Some clinicians have used the following guidelines (Aronoff 2007); <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Moderately dialyzable (20% to 50%): 20 to 40 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 20 to 40 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Initial loading dose of 1,000 to 2,000 mg, then:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute: 1,000 to 2,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute: 1,000 to 2,000 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 5 to 9 mL/minute: 500 to 1,000 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;5 mL/minute: 500 to 1,000 mg every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Moderately dialyzable (20% to 50%): Loading dose of 1,000 to 2,000 mg after each hemodialysis; maintenance dose as noted above based on CrCl</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147652\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mefoxin: 1 g (50 mL [DSC]); 2 g (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147636\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046029\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IVP: Administer over 3 to 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent IV infusion: Administer over 10 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus. <b>Note:</b> IM injection is painful and this route of administration is not described in the prescribing information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147668\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution store between 2&deg;C and 25&deg;C (36&deg;F and 77&deg;F). Avoid exposure to temperatures &gt;50&deg;C (122&deg;F). Cefoxitin tends to darken depending on storage conditions; however, product potency is not adversely affected.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> Reconstituted solutions of 1 g per 10 mL in sterile water for injection, bacteriostatic water for injection, sodium chloride 0.9% injection, or dextrose 5% injection are stable for 6 hours at room temperature or for 7 days under refrigeration (&lt;5&deg;C [43&deg;F]).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">DUPLEX container: Store unactivated container at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Following activation, solution is stable for 12 hours at room temperature and 7 days refrigerated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046028\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible lower respiratory tract, skin and skin structure, bone and joint, genitourinary tract, sepsis, gynecologic, and intra-abdominal infections and surgical prophylaxis (FDA approved in ages &ge;3 months and adults); has also been used in the prophylaxis of peritonitis in patients with peritoneal catheters undergoing gastrointestinal or genitourinary procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147726\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mefoxin may be confused with Lanoxin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147723\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, angioedema, bone marrow depression, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (increased; with aminoglycosides), phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, urticaria, vomiting </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147659\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147640\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; GI disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Children: In pediatric patients &ge;3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Discontinuation of therapy: For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298992\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147645\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13131&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5953484\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046025\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function periodically when used in combination with other nephrotoxic drugs; liver function and hematologic function tests; number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147639\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147658\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including ascitic, pleural, synovial, bile; poorly penetrates into CSF even with inflammation of the meninges (Landesman 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 65% to 79% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates and Infants (PNA: 10-53 days): 1.4 hours (Regazzi 1983); Adults: 41-59 minutes; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: Within 20-30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323049\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $7.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 4% (1): $13.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.2% (1): $24.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038555\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aboxitin (BD);</li>\n      <li>Acifox (PH);</li>\n      <li>Cefmore (TW);</li>\n      <li>Cefovex (PH);</li>\n      <li>Cefoxitin Sodium (AU);</li>\n      <li>Cefoxivit (PH);</li>\n      <li>Cefxitin (TH);</li>\n      <li>Cenomycin (JP);</li>\n      <li>Daliding (CN);</li>\n      <li>Dintaxin (PH);</li>\n      <li>Foxitane (BD);</li>\n      <li>Foxitin (AE, JO, QA, SA);</li>\n      <li>Irva (BD);</li>\n      <li>Jeitin (KR);</li>\n      <li>Lofatin (TW);</li>\n      <li>Mefoxil (GR);</li>\n      <li>Mefoxin (AE, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CY, CZ, EG, ET, FI, FR, GB, GH, GM, GN, GY, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PT, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Mefoxitin (AT, CH, DE, DK, NO, SE);</li>\n      <li>Merxin (JP);</li>\n      <li>Monodin (PH);</li>\n      <li>Monowel (PH);</li>\n      <li>Pacetin (KR);</li>\n      <li>Panafox (PH);</li>\n      <li>Sephros (MY);</li>\n      <li>Voxitin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zepax (PH);</li>\n      <li>Zepotin (PH);</li>\n      <li>Zoxin (JO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman WE, Moffitt S, and Sprow N, &ldquo;Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1980, 17(4):669-74. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7396456/pubmed\" target=\"_blank\" id=\"7396456\">7396456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCloskey RV. Intramuscular cefoxitin. <i>Rev Infect Dis</i>. 1979;1(1):224-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/400934 /pubmed\" target=\"_blank\" id=\"400934 \">400934 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regazzi MB, Chirico G, Cristiani D, et al, &ldquo;Cefoxitin in Newborn Infants. A Clinical and Pharmacokinetic Study,&rdquo; <i>Eur J Clin Pharmacol</i>, 1983, 25(4):507-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/6653646 /pubmed\" target=\"_blank\" id=\"6653646 \">6653646 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roos R, von Hattingberg HM, Belohradsky BH, et al. Pharmacokinetics of cefoxitin in premature and newborn infants studied by continuous serum level monitoring during combination therapy with penicillin and amikacin. <i>Infection</i>. 1980;8(6):301-306.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sonneville PF, Albert KS, Skeggs H, Gentner H, Kwan KC, Martin CM. Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. <i>Eur J Clin Pharmacol</i>. 1977;12(4):273-279. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/590313 /pubmed\" target=\"_blank\" id=\"590313 \">590313 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Berman S, and Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13131 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10327785\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14965749\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046026\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442225\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046019\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147652\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147636\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046029\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F147668\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046028\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147726\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147723\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147659\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147640\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298992\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147645\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5953484\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046025\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147639\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147658\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323049\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038555\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13131|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">Cefoxitin: Drug information</a></li><li><a href=\"topic.htm?path=cefoxitin-patient-drug-information\" class=\"drug drug_patient\">Cefoxitin: Patient drug information</a></li></ul></div></div>","javascript":null}